Traditional pharma manufacturers are already dipping their toes in the waters of continuous processing, but what about when it comes to biopharmaceuticals?

As politicians and the public argue over the minor point of the UK leaving Europe, we ask a more important question: what will a “Brexit” mean for the global pharmaceutical industry?

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

Our experience with implementing serialization, has shown us that anti-counterfeiting is just one of its potential uses.

Antibody drug conjugates offer a great deal of potential for drug targeting, but what’s the best way of linking drugs and antibodies?

Are the metrics used to measure cancer drug efficacy inherently flawed?

Where did Quality by Design come from? Where will it lead to in pharma? And is there a day when the concept will no longer exist?

The term ‘packaging’ may not immediately evoke excitement – but without innovation in the field, some therapies wouldn’t even reach market. In other words, don’t judge a box by its cover because there’s more to packaging than meets the eye… and even more lies on the horizon.

Can the stress of space force fungi to produce novel therapeutics?

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?